For: | Liu HR. Harnessing traditional medicine and biomarker-driven approaches to counteract Trichostatin A-induced esophageal cancer progression. World J Gastroenterol 2025; 31(20): 106443 [PMID: 40495945 DOI: 10.3748/wjg.v31.i20.106443] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v31/i20/106443.htm |
Number | Citing Articles |
1 |
Fei Yan, Jingni Zhu, Qibing Wu, Yuanyuan Ren, Xinnian Yu, Zijian Sun, Yang Liu, Changjiang Sun, Yan Sun. Real-world first-line serplulimab therapy for advanced esophageal cancer: effectiveness, safety, and clinical implications. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1637458
|
2 |
Yuanqing Zhao, Jin Xu, Ke Yang, Li Bao. Targeting GABA signaling in the tumor microenvironment: implications for immune cell regulation and immunotherapy resistance. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1645718
|
3 |
Yu Yang, Zhanping Guo. Prognostic value of Linc00662/miR-16-5p/FASN in cervical cancer and regulation of tumor progression. Hereditas 2025; 162(1) doi: 10.1186/s41065-025-00520-6
|